Navigation Links
PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance
Date:3/2/2010

179,739 168,403 184,400 167,869 ======= ======= ======= ======= (1) The financial results associated with both PDL's former commercial operations which were sold in March 2008 and PDL's former biotechnology operations which were spun off in December 2008 have been presented as discontinued operations for the quarter and year ended December 31, 2008. There were no discontinued operations for the quarter and year ended December 31, 2009. PDL BIOPHARMA, INC. CONDENSED CONSOLIDATED BALANCE SHEET DATA (in thousands) (unaudited) December 31, December 31, 2009 2008 ---- ---- Cash, cash equivalents, short-term investments and restricted cash $303,227 $147,527 Total assets $338,411 $191,142 Convertible notes payable $427,998 $499,998 Non-recourse notes payable $300,000 $- Total stockholders' deficit $(415,953) $(352,569) CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW DATA (in thousands) (unaudited)
'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies
2. Indiana Biopharmaceutical Service Providers Maintain Steady Growth Despite Industry Challenges
3. SynCo Bio Partners Signs New Manufacturing Agreements to Supply the US Market; Securing its Position as a Market Leader in Microbial Biopharmaceutical Contract Production
4. ClearTrial to Demonstrate Dramatic Gains in Clinical Outsourcing Efficiency Achieved by Biopharmaceutical Companies at European Outsourcing Event
5. Sinobiopharma Announces Second Quarter 2010 Financial Results
6. Microbix And Therapure Biopharma Form Partnership To Expand Water-Based Supplies To The Pharma Industry
7. YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract
8. Array BioPharma and Amgen Partner in Type 2 Diabetes
9. PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million
10. PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend
11. PDL BioPharma Announces Special Dividend Payment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... ... Ralco is honored to announce that it is the primary sponsor of ... 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the public ... daily lives. This unique exhibit also features a birthing center for fair goers to ...
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... , July 30, 2015 Ascendis ... company that applies its innovative TransCon technology to ... top-line results from a six-month Phase 2 study ... TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal children ... "We are extremely pleased with the top-line results ...
(Date:7/29/2015)... 30, 2015 Sanofi, a ... the second quarter of 2015. CEO Olivier ... its performance in different businesses. Watch ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in the ... - Performance drivers - Diabetes ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... is available in German . Leica ... and the German Cancer Research Center (DKFZ) for the development ... microscopy. This gives Leica Microsystems the license to develop the ... put it on the market. Stefan Hell, Director at ...
... dba Discharge 1-2-3 of Schaumburg, IL has ... Chicago Innovation Awards for their Discharge 1-2-3 Composer™. ... Harris Theater on Tuesday, November 8, with more than 1400 ... is the Chicago region,s foremost recognition of the most innovative ...
... by which a bacterial pathogen causes the deadly tropical disease ... The findings are published today in the journal ... the bacterium Burkholderia pseudomallei kills cells by preventing protein synthesis. ... way for the development of novel therapies to combat the ...
Cached Biology Technology:Gated STED -- developing the next generation of super-resolution microscopes 2Callibra, Inc. dba Discharge 1-2-3 is Named Winner of 2011 Chicago Innovation Award 2Callibra, Inc. dba Discharge 1-2-3 is Named Winner of 2011 Chicago Innovation Award 3Scientists defuse the 'Vietnam time bomb' 2
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:7/8/2015)... NEW YORK , July 8, 2015  BD ... announced BD & Guidepoint Mentor, a new ... to Guidepoint,s expert network services. BD ... technologies to improve healthcare delivery and outcomes and, with ... start-up entrepreneur will be able to directly engage with ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... in organic crop production is increasing around the ... environmental benefits and decreasing the amount of synthetic ... gain popularity with consumers, organic farmers are faced ... invasive weeds. Synthetic mulches, manufactured from petroleum-based ...
... relies on composted waste materials and byproducts, such as ... as a necessary nutrient source. Studies have shown that ... and hair salons, combined with additional compost, is an ... become commercially available to crop producers in the past ...
... UC Davis Cancer Center researchers report today the discovery ... form of cancer. The finding, which is published in ... of Nuclear Medicine and Molecular Imaging , provides hope ... the most common and aggressive type of primary brain ...
Cached Biology News:Organic plant waste proves effective weed control for citrus trees 2Organic plant waste proves effective weed control for citrus trees 3New use for human hair 2UC Davis researchers find molecule that targets brain tumors 2
XPC Immunogen: XPC (NP_004619, 141 a.a. ~ 251 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to Lck (phospho Y192) ( Abpromise for all tested applications). entrezGeneID: 3932 SwissProtID: P06239...
Anti 7H6 Antigen (tight-junction associated protein Antigen) Monoclonal Antibody 7H6...
Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
Biology Products: